Clinical Trial Update: A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating PF-05280014 (trastuzumab biosimilar) with Taxotere and carboplatin in HER2-positive breast cancer in the neoadjuvant setting has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PF-05280014 (PF-05280014)
• Taxotere (docetaxel)

Snippet

Sponsor: Pfizer | Conditions: Early Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-04-07